MedPath

PMCF Study on CranioFix®2 System Used for the Fixation of Craniotomized Bone Flaps and Fractures

Completed
Conditions
Skull Fractures
Registration Number
NCT05119595
Lead Sponsor
Aesculap AG
Brief Summary

The CranioFix®2 PMCF study has been set up as an action within the framework of a proactive post-market surveillance system of the manufacturer. The aim of this observational study is to collect systematically and proactively data regarding the performance of CranioFix®2, like adverse events (AEs), handling and cosmetic outcome, under daily clinical practice when used as intended by the manufacturer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  • Written informed consent
  • Age ≥ 18 years
  • Use of CranioFix®2 system according to IfU
  • Planned postoperative MRI within clinical routine
Exclusion Criteria
  • Pregnancy
  • Patients with hypersensitivity to metals or allergies to the implant materials
  • Inflammations in the region of the implant site
  • Bone conditions that rule out the application of CranioFix®2 titanium clamps
  • Use with artificial cranial bone flaps
  • Bone tumors in the area supporting the implant
  • Degenerative bone diseases
  • Missing dura mater
  • Application in the facial skull (viscerocranium) and in the orbital or skull-base region
  • Combination of implant components from different manufacturers, i.e. additional use of plates and screws on the same bone fragment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Planarity of Bone Flap After ImplantationThrough postoperative course: at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months after surgery)

The primary variable was the planarity of the bone flap after implantation. The bone flap planarity was evaluated as the rate of patients in which a dislocation of the bone flap occurred - defined as the height of the tilting (depression / protrusion) greater than the bone width.

Secondary Outcome Measures
NameTimeMethod
Number of Participants With Adverse Events (Intra- and Postoperative)through study completion, an average of 3 months

Number of adverse events e.g. foreign body reactions, infections, injury to the dura, injury to the scalp, epiduralhaematoma, wound healing disorders with special focus on (serious) adverse events with (possible) relation to the investigational product

Overall Handling of Instruments for CranioFix®2 System Implantation Documented on a Likert Scaleintraoperative

Assessment of handling, documented on a Likert scale 1 to 5 (1 is the very good, 2 is good, 3 is acceptable, 4 is poor, 5 is very poor)

Stability of the Bone Flap After Fixationintraoperative, at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)

Assessment of stability of the bone flap, documented on a Likert scale 1 to 5 (1≙very good, 2≙good, 3≙medium, 4≙poor, 5≙very poor)

Cosmetic Outcomeintraoperative, at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)

Assessment of cosmetic outcome intraoperatively, at discharge and at post-operative follow-up documented on a 3 point scale (good, fair, bad)

Trial Locations

Locations (1)

Klinikum Stuttgart - Katharinenhospital

🇩🇪

Stuttgart, Germany

© Copyright 2025. All Rights Reserved by MedPath